Apogee Therapeutics (APGE) to Release Earnings on Monday

Key Points

• Apogee Therapeutics will report Q1 2026 results before the market opens on Monday, May 11, with analysts projecting ($1.12) EPS and a conference call set for May 12 at 9:30 AM ET.
• APGE recently traded around $83.81 (market cap ~$5.18B) and carries a consensus rating of "Moderate Buy" with an average target of $112.73 following multiple analyst upgrades.
• Insiders have been net sellers — including the CEO's sale of 20,000 shares — with 76,500 shares sold in the past 90 days, while insiders still own 24.3% and institutions hold about 79% of the stock.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) is projected to release its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Apogee Therapeutics to post earnings of ($1.12) per share for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 9:30 AM ET.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, beating analysts' consensus estimates of ($1.05) by $0.02. On average, analysts expect Apogee Therapeutics to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Apogee Therapeutics Price Performance

Shares of APGE stock traded up $3.06 during trading hours on Monday, reaching $83.81. 219,325 shares of the company traded hands, compared to its average volume of 971,806. Apogee Therapeutics has a 12-month low of $34.34 and a 12-month high of $95.32. The company has a market cap of $5.18 billion, a P/E ratio of -19.89 and a beta of 0.69. The firm has a 50-day moving average price of $78.89 and a 200 day moving average price of $72.41.

Analyst Ratings Changes

APGE has been the topic of several recent analyst reports. Citigroup lifted their target price on Apogee Therapeutics from $95.00 to $125.00 and gave the company a "buy" rating in a research note on Tuesday, March 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Apogee Therapeutics in a research note on Monday, April 20th. Wedbush lifted their target price on Apogee Therapeutics from $90.00 to $95.00 and gave the company an "outperform" rating in a research note on Tuesday, March 3rd. Truist Financial initiated coverage on Apogee Therapeutics in a research note on Tuesday, March 17th. They set a "hold" rating and a $83.00 target price on the stock. Finally, UBS Group raised Apogee Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $112.73.

Insider Buying and Selling

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $84.84, for a total value of $466,620.00. Following the sale, the insider owned 208,398 shares of the company's stock, valued at $17,680,486.32. The trade was a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $82.58, for a total value of $1,651,600.00. Following the completion of the sale, the chief executive officer directly owned 1,132,987 shares in the company, valued at approximately $93,562,066.46. The trade was a 1.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 76,500 shares of company stock worth $5,633,495. Corporate insiders own 24.30% of the company's stock.

Hedge Funds Weigh In On Apogee Therapeutics

Large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its position in shares of Apogee Therapeutics by 27.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 80,832 shares of the company's stock valued at $6,118,000 after purchasing an additional 17,607 shares during the last quarter. Two Sigma Investments LP increased its position in shares of Apogee Therapeutics by 5.8% during the 3rd quarter. Two Sigma Investments LP now owns 122,375 shares of the company's stock valued at $4,862,000 after purchasing an additional 6,681 shares during the last quarter. Swiss National Bank increased its position in shares of Apogee Therapeutics by 44.9% during the 4th quarter. Swiss National Bank now owns 62,900 shares of the company's stock valued at $4,748,000 after purchasing an additional 19,500 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Apogee Therapeutics by 93.3% during the 4th quarter. Wells Fargo & Company MN now owns 42,499 shares of the company's stock valued at $3,208,000 after purchasing an additional 20,509 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in shares of Apogee Therapeutics during the 4th quarter valued at approximately $2,267,000. Institutional investors own 79.04% of the company's stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.